

2003–2004 ACS Division of Medicinal Chemistry Predoctoral Fellowship Awards

Five graduate students are recipients of the ACS Division of Medicinal Chemistry 2003–2004 Predoctoral Fellowship. The division annually awards five predoctoral fellowships for a period of one year to a third or fourth year graduate student engaged in medicinal chemistry research. Each fellowship is sponsored by a pharmaceutical company and consists of a \$20,000 stipend and travel funds to attend the Fall ACS meeting, where the awardees will orally present their research results in an award symposium.

William Greenlee
Chair, Division of Medicinal Chemistry Graduate Program
Schering-Plough Research Institute, October 23, 2003



Andrew P. Brogan

Sponsor: Bristol-Myers Squibb

University: *University of North Carolina at
Chapel Hill*

Advisor: Harold Kohn

Andrew P. Brogan received a B.A. in Chemistry and a B.S. in Biochemistry from Virginia Tech while conducting undergraduate research with Richard D. Gandour and James F. Wolfe. During his tenure at Virginia Tech, he also spent a summer as an undergraduate research fellow in John F. Stobaugh's laboratory in the pharmaceutical chemistry department at the University of Kansas. Currently, he is a fifth year graduate student in medicinal chemistry at the University of North Carolina at Chapel Hill studying bicyclomycin analogues as mechanistic probes of the transcription termination factor rho with Harold Kohn.



Scott M. Capitosti

Sponsor: Wyeth Pharmaceuticals

University: *University of Virginia*

Advisor: Milton L. Brown


Scott M. Capitosti received a B.S. degree in Chemistry from the University of Pittsburgh at Johnstown, where he worked with Dr. George B. Trimitsis on the use of silyl enol ethers as chiral homoenolate equivalents. He is currently a fourth year graduate student in the department of chemistry at the University of Virginia, working under Dr. Milton L. Brown. His Ph.D. research is focused on the design and synthesis of novel thalidomide mimics as dual inhibitors of both angiogenesis and cancer cell proliferation.



Michael L. Mohler

Sponsor: Eli Lilly and Company
University: University of Tennessee
Advisor: Duane D. Miller

Michael L. Mohler received a B.S. in Chemistry and Biology (double major) from the University of Tennessee at Martin. He worked for Dr. Engin H. Serspersu at the University of Tennessee, Knoxville, earning an M.S. in biochemistry studying enzyme-mediated antibiotic resistance using NMR techniques. He joined the Pharm.D./Ph.D. program at the University of Tennessee Health Science Center in Memphis, where he has completed his Pharm.D. and is currently working for Dr. Duane D. Miller pursuing his Ph.D. His research project involves the drug design of envelope-specific hepatitis C anti-viral agents and the development of assays for screening putative antivirals for blocking virus binding to cells and preventing infectivity.



John Schneekloth, Jr.

Sponsor: Aventis Pharmaceuticals
University: Yale University
Advisor: Craig Crews

John Schneekloth, Jr., received an A.B. from Dartmouth College in 2001. As an undergraduate, he worked under the supervision of Professor Gordon Gribble on the total synthesis of several halogenated bipyrrrole natural products. He is currently a third year student in the Ph.D. program at Yale University in the Department of Chemistry. His graduate research, under the direction of Professor Craig Crews, is directed toward natural product total synthesis and the synthesis of designed molecules that affect targeted protein degradation.



Anthony Jon (A. J.) Roecker

Sponsor: Pfizer Global Research & Development
University: Scripps Research Institute
Advisor: K. C. Nicolaou

Anthony Jon (A. J.) Roecker received his B.S. degree in Chemistry from the Ohio State University in 1999 while working in the laboratory of Jonathan Parquette on aspects of dendrimer chemistry. Currently, he is a fourth year graduate student at the Scripps Research Institute working under the guidance of Professor K. C. Nicolaou. His work includes efforts toward the total synthesis of the potent antifeedant azadirachtin as well as the design of novel natural product-like combinatorial libraries and their application to chemical biology.

OL030128W